Skip to main content

Table 3 Serum supplemented with TNF-α/EGF/EGFR inhibitor, open wound surface area (%) of the original at 48 h

From: Inhibitory effects of serum from sepsis patients on epithelial cell migration in vitro: a case control study

Serum

Cytokine

Amount of cytokine

Number of wounds

Mean  % (SD)

P value

Healthy (control)

8

61 (15)

 

Sepsis (control)

8

75 (20)

 

Healthy

TNF-α

5 ng/ml

8

14 (15)

<0.001

Sepsis

TNF-α

5 ng/ml

7

44 (19)

0.009

Healthy

TNF-α

10 ng/ml

7

13 (15)

<0.001

Sepsis

TNF-α

10 ng/ml

5

30 (20)

0.002

Healthy

TNF-α

50 ng/ml

6

7 (16)

0.002

Sepsis

TNF-α

50 ng/ml

5

16 (18)

0.005

Healthy

EGF

5 ng/ml

6

0 (0)

0.001

Sepsis

EGF

5 ng/ml

8

2 (5)

0.001

Healthy

EGF

10 ng/ml

8

9 (17)

0.001

Sepsis

EGF

10 ng/ml

6

72 (57)

0.301

Healthy

EGF

50 ng/ml

4

51 (59)

0.768

Sepsis

EGF

50 ng/ml

6

77 (39)

0.887

Healthy

EGFr inhibitor

1 µg/ml

7

84 (24)

0.037

Sepsis

EGFr inhibitor

1 µg/ml

7

96 (7)

0.008

Healthy

EGFr inhibitor

10 µg/ml

5

95 (11)

0.001

Sepsis

EGFr inhibitor

10 µg/ml

6

106 (10)

0.005

Healthy

EGFr inhibitor

50 µg/ml

7

95 (4)

0.001

Sepsis

EGFr inhibitor

50 µg/ml

7

99 (2)

0.001

  1. Healthy serum samples are compared to healthy control serum and sepsis serum samples to sepsis control serum. Significant P values are in italic